Literature DB >> 23608121

Clinically important differences in the intensity of chronic refractory breathlessness.

Miriam J Johnson1, J Martin Bland, Stephen G Oxberry, Amy P Abernethy, David C Currow.   

Abstract

CONTEXT: Clinically important differences in chronic refractory breathlessness are ill defined but important in clinical practice and trial design.
OBJECTIVES: To estimate the clinical relevance of differences in breathlessness intensity using distribution and patient anchor methods.
METHODS: This was a retrospective data analysis from 213 datasets from four clinical trials for refractory breathlessness. Linear regression was used to explore the relationship between study effect size and change in breathlessness score (0-100mm visual analogue scale) and to estimate the change in score equivalent to small, moderate, and large effect sizes. Pooled individual blinded patient preference data from three randomized controlled trials were analyzed. The difference between the mean change in Day 4 minus baseline scores between preferred and non-preferred arms was calculated.
RESULTS: There was a strong relationship between change in score and effect size (P = 0.001; R(2) = 0.98). Values for small, moderate, and large effects were -5.5, -11.3, and -18.2mm. The participant preference change in score was -9mm (95% CI, -15.8, -2.1) (P = 0.008).
CONCLUSION: This larger dataset supports a clinically important difference of 10mm. Studies should be powered to detect this difference.
Copyright © 2013 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Minimal clinically important difference; breathlessness; dyspnea; opioid

Mesh:

Year:  2013        PMID: 23608121     DOI: 10.1016/j.jpainsymman.2013.01.011

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  25 in total

1.  Cross-cultural measurement equivalence of the EQ-5D-5L items for English-speaking Asians in Singapore.

Authors:  N Luo; Y Wang; C H How; K Y Wong; L Shen; E G Tay; J Thumboo; M Herdman
Journal:  Qual Life Res       Date:  2014-11-14       Impact factor: 4.147

2.  Effects of Oral Morphine on Dyspnea in Patients with Cancer: Response Rate, Predictive Factors, and Clinically Meaningful Change (CJLSG1101).

Authors:  Kosuke Takahashi; Masashi Kondo; Masahiko Ando; Akira Shiraki; Harunori Nakashima; Hisashi Wakayama; Kensuke Kataoka; Masashi Yamamoto; Yasuteru Sugino; Mitsunori Nishikawa; Kazuyoshi Imaizumi; Eiji Kojima; Atsushi Sumida; Yoshihiro Takeyama; Hiroshi Saito; Yoshinori Hasegawa
Journal:  Oncologist       Date:  2019-01-18

3.  Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients.

Authors:  Robert W Hallowell; Richard Schwartzstein; Carl R O'Donnell; Andrew Sheridan; Robert B Banzett
Journal:  Lung       Date:  2019-11-15       Impact factor: 2.584

4.  The longitudinal pattern of response when morphine is used to treat chronic refractory dyspnea.

Authors:  David C Currow; Stephen Quinn; Aine Greene; Janet Bull; Miriam J Johnson; Amy P Abernethy
Journal:  J Palliat Med       Date:  2013-06-08       Impact factor: 2.947

Review 5.  Opioids for chronic refractory breathlessness: right patient, right route?

Authors:  David C Currow; Magnus Ekstrom; Amy P Abernethy
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

6.  Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial.

Authors:  Cornelia A Verberkt; Marieke H J van den Beuken-van Everdingen; Jos M G A Schols; Niels Hameleers; Emiel F M Wouters; Daisy J A Janssen
Journal:  JAMA Intern Med       Date:  2020-10-01       Impact factor: 21.873

7.  A randomised, double-blind controlled trial of intranasal midazolam for the palliation of dyspnoea in patients with life-limiting disease.

Authors:  Janet Hardy; Clare Randall; Eve Pinkerton; Christopher Flatley; Kristen Gibbons; Simon Allan
Journal:  Support Care Cancer       Date:  2016-02-18       Impact factor: 3.603

8.  Cross-cultural measurement equivalence of the 5-level EQ-5D (EQ-5D-5L) in patients with type 2 diabetes mellitus in Singapore.

Authors:  Ye Wang; Ngiap-Chuan Tan; Ee-Guan Tay; Julian Thumboo; Nan Luo
Journal:  Health Qual Life Outcomes       Date:  2015-07-16       Impact factor: 3.186

9.  Who experiences higher and increasing breathlessness in advanced cancer? The longitudinal EPCCS Study.

Authors:  M Ekström; M J Johnson; L Schiöler; S Kaasa; M J Hjermstad; D C Currow
Journal:  Support Care Cancer       Date:  2016-04-09       Impact factor: 3.603

10.  Predictors of Morphine Efficacy for Dyspnea in Inpatients with Chronic Obstructive Pulmonary Disease: A Secondary Analysis of JORTC-PAL 07.

Authors:  Yoshinobu Matsuda; Tatsuya Morita; Hirotaka Matsumoto; Keita Hosoi; Kayo Kusama; Yasuo Kohashi; Hiroshi Morishita; Sawako Kaku; Keisukie Ariyoshi; Shunsuke Oyamada; Yoshikazu Inoue; Satoru Iwase; Takuhiro Yamaguchi; Mitsunori Nishikawa
Journal:  Palliat Med Rep       Date:  2021-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.